286 related articles for article (PubMed ID: 17010496)
21. Gold(I)-mediated inhibition of protein tyrosine phosphatases: a detailed in vitro and cellular study.
Krishnamurthy D; Karver MR; Fiorillo E; Orrú V; Stanford SM; Bottini N; Barrios AM
J Med Chem; 2008 Aug; 51(15):4790-5. PubMed ID: 18605719
[TBL] [Abstract][Full Text] [Related]
22. Design of compound libraries based on natural product scaffolds and protein structure similarity clustering (PSSC).
Balamurugan R; Dekker FJ; Waldmann H
Mol Biosyst; 2005 May; 1(1):36-45. PubMed ID: 16880961
[TBL] [Abstract][Full Text] [Related]
23. Rational approaches to natural-product-based drug design.
Haustedt LO; Mang C; Siems K; Schiewe H
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):445-62. PubMed ID: 16889228
[TBL] [Abstract][Full Text] [Related]
24. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery.
Zhang S; Zhang ZY
Drug Discov Today; 2007 May; 12(9-10):373-81. PubMed ID: 17467573
[TBL] [Abstract][Full Text] [Related]
25. Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases.
Zhang ZY
Acc Chem Res; 2017 Jan; 50(1):122-129. PubMed ID: 27977138
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Mycobacterium tuberculosis protein tyrosine phosphatase A (MptpA) inhibitors based on natural products and a fragment-based approach.
Manger M; Scheck M; Prinz H; von Kries JP; Langer T; Saxena K; Schwalbe H; Fürstner A; Rademann J; Waldmann H
Chembiochem; 2005 Oct; 6(10):1749-53. PubMed ID: 16196020
[No Abstract] [Full Text] [Related]
27. Protein tyrosine phosphatase inhibitors: a patent review (2002 - 2011).
Sobhia ME; Paul S; Shinde R; Potluri M; Gundam V; Kaur A; Haokip T
Expert Opin Ther Pat; 2012 Feb; 22(2):125-53. PubMed ID: 22332719
[TBL] [Abstract][Full Text] [Related]
28. Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibitors: capturing interactions with Asp48.
Wan ZK; Lee J; Xu W; Erbe DV; Joseph-McCarthy D; Follows BC; Zhang YL
Bioorg Med Chem Lett; 2006 Sep; 16(18):4941-5. PubMed ID: 16806920
[TBL] [Abstract][Full Text] [Related]
29. Inhibition studies with rationally designed inhibitors of the human low molecular weight protein tyrosine phosphatase.
Zabell AP; Corden S; Helquist P; Stauffacher CV; Wiest O
Bioorg Med Chem; 2004 Apr; 12(8):1867-80. PubMed ID: 15051056
[TBL] [Abstract][Full Text] [Related]
30. Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors.
Moretto AF; Kirincich SJ; Xu WX; Smith MJ; Wan ZK; Wilson DP; Follows BC; Binnun E; Joseph-McCarthy D; Foreman K; Erbe DV; Zhang YL; Tam SK; Tam SY; Lee J
Bioorg Med Chem; 2006 Apr; 14(7):2162-77. PubMed ID: 16303309
[TBL] [Abstract][Full Text] [Related]
31. A protected l-bromophosphonomethylphenylalanine amino acid derivative (BrPmp) for synthesis of irreversible protein tyrosine phosphatase inhibitors.
Tulsi NS; Downey AM; Cairo CW
Bioorg Med Chem; 2010 Dec; 18(24):8679-86. PubMed ID: 21055952
[TBL] [Abstract][Full Text] [Related]
32. PTP-1B inhibitors: cyclopenta[d][1,2]-oxazine derivatives.
Cho SY; Baek JY; Han SS; Kang SK; Ha JD; Ahn JH; Lee JD; Kim KR; Cheon HG; Rhee SD; Yang SD; Yon GH; Pak CS; Choi JK
Bioorg Med Chem Lett; 2006 Feb; 16(3):499-502. PubMed ID: 16289879
[TBL] [Abstract][Full Text] [Related]
33. The development of potent non-peptidic PTP-1B inhibitors.
Dufresne C; Roy P; Wang Z; Asante-Appiah E; Cromlish W; Boie Y; Forghani F; Desmarais S; Wang Q; Skorey K; Waddleton D; Ramachandran C; Kennedy BP; Xu L; Gordon R; Chan CC; Leblanc Y
Bioorg Med Chem Lett; 2004 Feb; 14(4):1039-42. PubMed ID: 15013019
[TBL] [Abstract][Full Text] [Related]
34. Engineering the catalytic domain of human protein tyrosine phosphatase beta for structure-based drug discovery.
Evdokimov AG; Pokross M; Walter R; Mekel M; Cox B; Li C; Bechard R; Genbauffe F; Andrews R; Diven C; Howard B; Rastogi V; Gray J; Maier M; Peters KG
Acta Crystallogr D Biol Crystallogr; 2006 Dec; 62(Pt 12):1435-45. PubMed ID: 17139078
[TBL] [Abstract][Full Text] [Related]
35. Drug discovery and protein tyrosine phosphatases.
Blaskovich MA
Curr Med Chem; 2009; 16(17):2095-176. PubMed ID: 19519384
[TBL] [Abstract][Full Text] [Related]
36. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine phosphatases such as SHP-2 act in a balance with Src-family kinases in stabilization of postsynaptic clusters of acetylcholine receptors.
Camilleri AA; Willmann R; Sadasivam G; Lin S; Rüegg MA; Gesemann M; Fuhrer C
BMC Neurosci; 2007 Jul; 8():46. PubMed ID: 17605785
[TBL] [Abstract][Full Text] [Related]
38. 5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors.
Ottanà R; Maccari R; Ciurleo R; Paoli P; Jacomelli M; Manao G; Camici G; Laggner C; Langer T
Bioorg Med Chem; 2009 Mar; 17(5):1928-37. PubMed ID: 19217304
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and inhibition activity of novel cyclic peptides against protein tyrosine phosphatase A from Mycobacterium tuberculosis.
Chandra K; Dutta D; Das AK; Basak A
Bioorg Med Chem; 2010 Dec; 18(23):8365-73. PubMed ID: 21050767
[TBL] [Abstract][Full Text] [Related]
40. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.
Taha MO; Bustanji Y; Al-Bakri AG; Yousef AM; Zalloum WA; Al-Masri IM; Atallah N
J Mol Graph Model; 2007 Mar; 25(6):870-84. PubMed ID: 17035054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
